FinalDose GTM brain

FinalDose is developing a programmable DNA-recognition approach to cancer therapeutics, with potential research and pharmaceutical partners.

category

Programmable oncology therapeutics

market profile

  • text: FinalDose proposes a sequence-directed approach for genetically defined cancer targets; its therapeutic claims remain to be clinically established.
  • text: The company is at an early research stage; an independent industry profile reported no public trial or named clinical program.
  • text: Targeted oncology development faces delivery, tumor specificity and translational evidence hurdles.

personas

  • title: Oncology pharmaceutical business development lead
    pains:
    • Finding differentiated approaches to difficult cancer targets.
    • Determining whether preclinical data justify a licensing or co-development investment.
  • title: Translational oncology research director
    pains:
    • Conventional modalities cannot address every genetically defined target.
    • Needs reproducible selectivity, delivery and safety evidence before advancing a platform.
  • title: Biotech investor focused on oncology
    pains:
    • Separating a broad therapeutic vision from validated milestones.
    • Financing long studies while managing scientific and regulatory risk.

icp

  • text: Potential future partners include pharmaceutical companies with oncology pipelines and teams evaluating novel modality licensing; partnerships are not confirmed.
  • text: Academic cancer research groups and translational research centers are plausible collaborators, subject to validation of the platform and actual partnership interest.

message pillars

  • text: Frame DNA recognition as the address for targeting.
  • text: Present programmability as a potential route to scale across targets.
  • text: Express cell elimination as the company's therapeutic ambition, not a proven cure.

objections

  • objection: Has this been proven safe and effective in patients?
    response: Request published stage-specific efficacy and safety evidence; the accessible sources do not establish clinical efficacy.
  • objection: Can the therapy reach sufficient tumor cells?
    response: Ask for delivery and tumor selectivity evidence by indication; delivery is a stated development challenge.

competitors

  • name: Senti Bio
    why: Develops programmable gene-circuit cancer cell therapies, an alternative approach to selective killing.
  • name: ArsenalBio
    why: Develops programmable cell therapies for cancer, a different precision oncology modality.

influencers

  • name: Li-Yao Huang
    url: https://www.linkedin.com/posts/li-yao-huang-13676b1b2_finaldose-y-combinator-p26-here-we-are-activity-7447411659180040192-PRe0
    why: Co-founder described the company's cancer research ambition.
  • name: Jeff Liu
    url: https://www.ycombinator.com/founders/jeff-liu
    why: CEO and co-founder with an oncology research background.

keywords

  • programmable cancer therapeutics
  • DNA targeting cancer therapy
  • genetically defined cancer targets
  • precision oncology drug discovery
  • tumor selective therapy
  • programmable oncology platform

voice

  • Ambitious
  • Scientific
  • Declarative

signals

  • text: An oncology portfolio is seeking new ways to address hard-to-drug genetic targets.
  • text: A translational research group is investigating programmable and tumor-selective therapeutics.

pricing

model: unknown

motion

unknown

channels

  • YC launch
  • LinkedIn
  • Whitepaper

confidence

low

Founders

  • name: Jeff Liu
    title: Founder/CEO
    role: CEO
    bio: CEO @ FinalDose (YC P26). Oxford PhD in Oncology. Previous startup (Vivid Dx) solved a multi-decade bottleneck in sepsis diagnostics: low biomass isolation. By overcoming this hurdle, we built the world’s fastest diagnostic system - slashing wait times from 5 days to just 30 minutes. Raised $15M in venture backing.
  • name: Li-Yao Huang
    title: Founder
    role: Founder
    bio: Founder at FinalDose (YC P26). DPhil in Biochemistry from Oxford, where he spent 5 years as a postdoctoral researcher at the MRC Weatherall Institute of Molecular Medicine. Led CRISPR screening projects uncovering new druggable targets in cancer cells and built pipelines reducing hit validation time from months to 7 days. Research focuses on BRCA1-deficient cancers and PARP inhibitor resistance mechanisms.
  • name: Steven Lin
    title: Founder
    role: Founder
    bio: Cofounder and CTO at FinalDose (YC P26). Oxford PhD in Computational Biology with Wellcome Trust full scholarship. Previously Data Lead at Gutsee Biotech. Developed novel machine learning method to use coevolution biology to identify genetic targets that convey drug resistance in viruses. During SARS-CoV-2 pandemic, led UK biobank analysis of human genetics susceptibility for infections

Back to YC companies